Preliminary results from a Phase I/IIa study showed that one dose of Bioverativ's BIVV001, or rFVIIIFc-VWF-XTEN, resulted in a significant rise of factor VIII levels for seven days in people with severe hemophilia A, while also increasing factor VIII's half-life to 44 hours. The findings were presented at the American Society of Hematology's annual conference in December.
Bioverativ reports on preliminary data for factor VIII candidate
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.